Show simple item record

Article

dc.creatorThoenes, Martines
dc.creatorMinguet, Joanes
dc.creatorBramlage, Karines
dc.creatorBramlage, Peteres
dc.creatorFerrero Rodríguez, Carmenes
dc.date.accessioned2023-12-22T08:48:46Z
dc.date.available2023-12-22T08:48:46Z
dc.date.issued2016-11
dc.identifier.citationThoenes, M., Minguet, J., Bramlage, K., Bramlage, P. y Ferrero Rodríguez, C. (2016). Betrixaban – the next direct factor Xa inhibitor?. Expert Review of Hematology, 9 (12), 1111-1117. https://doi.org/10.1080/17474086.2016.1256194.
dc.identifier.issn1747-4094es
dc.identifier.urihttps://hdl.handle.net/11441/152774
dc.description.abstractIntroduction: Venous thromboembolism is a major global health burden. Since the 1930s, prevention of stroke and pulmonary embolism in these patients has been achieved using conventional anticoagulants, such as heparin and warfarin. However, in recent years, four direct non-vitamin K antagonist oral anticoagulants (DOACs) have entered the market as alternative treatment options. Betrixaban is a fifth DOAC looking to gain marketing approval in the near future, and may have several potentially beneficial properties. Areas covered: Here, we outline the metabolism, pharmacokinetics, and pharmacodynamics of betrixaban, and summarise its clinical efficacy and safety based on the results of phase II/III trials. Expert commentary: Betrixaban has been demonstrated to have antithrombotic activity that may make it a valuable addition to the repertoire of DOACs currently available. The low renal clearance and minimal hepatic metabolism of the drug may make it particularly beneficial for patients with renal or hepatic dysfunction. The lack of an effective reversal agent may be a more significant issue for betrixaban compared with the already approved DOACs as it has a longer terminal half-life. Available data suggest that continued development of betrixaban is justified; however, further large randomised clinical trials are essential in order to clarify its efficacy and safety.es
dc.formatapplication/pdfes
dc.format.extent7 p.es
dc.language.isoenges
dc.publisherTaylor & Francises
dc.relation.ispartofExpert Review of Hematology, 9 (12), 1111-1117.
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectBetrixabanes
dc.subjectFactor Xa inhibitorses
dc.subjectVenous thromboembolismes
dc.subjectAnticoagulantses
dc.subjectDOACes
dc.titleBetrixaban – the next direct factor Xa inhibitor?es
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/acceptedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Farmacia y Tecnología Farmacéuticaes
dc.relation.publisherversionhttps://dx.doi.org/10.1080/17474086.2016.1256194es
dc.identifier.doi10.1080/17474086.2016.1256194es
dc.journaltitleExpert Review of Hematologyes
dc.publication.volumen9es
dc.publication.issue12es
dc.publication.initialPage1111es
dc.publication.endPage1117es

FilesSizeFormatViewDescription
10.108017474086.2016.1256194.pdf614.7KbIcon   [PDF] View/Open   Versión aceptada

This item appears in the following collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
Except where otherwise noted, this item's license is described as: Atribución-NoComercial 4.0 Internacional